Under the Part D Senior Savings Model, Medicare recipients in participating plans will pay no more than a $35 copay for a month’s supply of insulin. The change is an effort to combat the dramatic rise ...
The Medicare program effectively reduced insulin costs, improved adherence, and increased plan enrollment, benefiting both patients and the federal government. The initiative involved major insulin ...
WASHINGTON, March 12-- The Pharmaceutical Care Management Association issued the following statement by President and CEO JC Scott regarding announcement from the Centers for Medicare and Medicaid ...
CMS’ Part D Senior Savings Model effectively increased insulin use while reducing out-of-pocket costs among Medicare beneficiaries, according to a RAND report published Sept. 22. The program also ...
The Part D Senior Savings Model - which was announced on March 11, 2020 - is a voluntary model that tests the impact on insulin access and care by participating Part D enhanced alternative plans ...
The Medicare prescription drug plan redesign under the Inflation Reduction Act of 2022 aims to simplify the Part D benefit while capping out-of-pocket spending for Part D–covered drugs. Whether and ...
Sarah Dalton, MA, is a senior policy analyst at RAND. She served as project manager and a qualitative data collection and analysis team member for the Part D Senior Savings Model evaluation. Her ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback